Mereo BioPharma Group (NASDAQ:MREO) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.
Stock analysts at JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) in a research report issued on Thursday, MarketBeat reports. The brokerage set an “overweight” rating and a $7.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 204.35% […]
Stock analysts at JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) in a research report issued on Thursday, MarketBeat reports. The brokerage set an “overweight” rating and a $7.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 204.35% […]
